Last updated: August 25, 2026
Pembrolizumab, marketed by Merck & Co. as Keytruda, is the largest oncology biologic by global sales. Revenue rose from $11.1 billion in 2019 to $29.5 billion in 2024, driven by label expansion, earlier-line use, combination regimens, and growth outside the United States. The commercial risk profile is changing from expansion-led growth to lifecycle management as U.S. biologic exclusivity approaches expiration in 2026 and core U.S. patent protection is expected to extend through 2028. [1]
How large is the pembrolizumab market?
Keytruda generated approximately $29.5 billion in 2024 revenue, representing about 46% of Merck's total pharmaceutical sales. The product remains the primary financial engine of Merck's human health business. [1]
| Fiscal year |
Keytruda revenue |
Year-over-year growth |
| 2019 |
$11.1 billion |
62% |
| 2020 |
$14.4 billion |
29% |
| 2021 |
$17.2 billion |
19% |
| 2022 |
$21.2 billion |
23% |
| 2023 |
$25.0 billion |
18% |
| 2024 |
$29.5 billion |
18% |
Source: Merck annual reports. [1]
Keytruda's growth has been unusually durable for a mature biologic. The product benefits from more than 40 FDA-approved indications across solid tumors and hematologic malignancies, including non-small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancer, triple-negative breast cancer, cervical cancer, endometrial cancer, bladder cancer, esophageal cancer, and colorectal cancer. [2]
Which therapeutic segments drive pembrolizumab sales?
The main commercial drivers are:
- Non-small cell lung cancer, where pembrolizumab is used as monotherapy in selected patients and in chemotherapy combinations.
- Melanoma, one of the original high-value indications.
- Renal cell carcinoma, where Keytruda is combined with axitinib or lenvatinib.
- Triple-negative breast cancer, including early-stage and metastatic disease.
- Gastrointestinal, gynecologic, and head and neck cancers.
- Earlier-line and perioperative treatment, which increases duration of therapy and eligible patient volume.
The strongest growth mechanism has been expansion into earlier disease settings. Adjuvant and neoadjuvant use increases treatment exposure before metastatic progression, although it also increases payer scrutiny and the need for outcome-based evidence.
What is the financial trajectory for Keytruda?
Keytruda's financial trajectory has three phases: rapid adoption from 2014 through 2019, broad label expansion from 2020 through 2024, and a projected transition toward peak sales followed by erosion after biosimilar or follow-on competition.
2014 to 2019: rapid immuno-oncology adoption
FDA first approved pembrolizumab in September 2014 for advanced melanoma. Merck expanded the product into lung cancer and other tumor types through accelerated and regular approval pathways. The early commercial model relied on high unmet need, premium pricing, and broad physician adoption of PD-1 therapy. [2]
2020 to 2024: indication expansion and combination growth
Revenue grew from $14.4 billion in 2020 to $29.5 billion in 2024. The compound annual growth rate over that period was approximately 19%. Growth came from:
- New approvals in breast, renal, gynecologic, gastrointestinal, and urothelial cancers.
- Increased use in earlier lines of therapy.
- Combination regimens with chemotherapy and targeted agents.
- International launches and reimbursement expansion.
- Greater diagnosis and treatment of cancer after pandemic-related disruptions.
Merck's 2024 annual report identifies Keytruda as the company's largest product and states that sales increased primarily because of higher demand from launches and continued uptake in earlier lines of therapy. [1]
2025 onward: peak-sales management
The product is likely to remain a multibillion-dollar franchise after initial biosimilar entry because oncology treatment is indication-specific and physician adoption is fragmented. The largest risks are loss of exclusivity, price compression, tender competition, switching to biosimilars, and substitution by rival checkpoint inhibitors.
Merck's lifecycle strategy includes:
- Subcutaneous or otherwise more convenient delivery.
- Fixed-dose and shortened administration options.
- New combinations with targeted agents, antibody-drug conjugates, and vaccines.
- Expansion into perioperative treatment.
- Companion diagnostics and biomarker-defined populations.
- Commercial agreements supporting next-generation cancer immunotherapies.
The strategic objective is to preserve treatment volume and reduce exposure to infusion-center economics after the core intravenous product loses exclusivity.
When does pembrolizumab lose regulatory exclusivity?
Keytruda received FDA approval on September 4, 2014. Under the Biologics Price Competition and Innovation Act, an innovator biologic receives 12 years of reference-product exclusivity from first licensure. The statutory data-exclusivity period therefore runs to September 2026. [3]
Regulatory exclusivity does not automatically permit biosimilar marketing. A biosimilar applicant must still address patents, provide the required analytical and clinical package, and obtain FDA approval under the 351(k) pathway.
| Event |
Date or period |
| First FDA approval of Keytruda |
September 4, 2014 |
| BLA |
125514 |
| Statutory U.S. biologic exclusivity |
Through approximately September 2026 |
| Company-reported core U.S. patent protection |
Expected through 2028 |
| Company-reported protection in major European markets |
Expected through approximately 2030 |
| Potential commercial biosimilar window |
Dependent on patents, litigation, settlements, and FDA approval |
The practical loss-of-exclusivity date is therefore later than the regulatory exclusivity date. For a product of Keytruda's value, patent settlements and launch timing are likely to have greater commercial importance than the September 2026 statutory milestone.
What patents protect pembrolizumab?
Pembrolizumab is protected by a layered patent estate covering the antibody, formulations, manufacturing, dosing, combinations, and methods of treating particular cancers.
Core antibody patents
The foundational estate covers anti-PD-1 antibodies and related sequences. Merck has identified U.S. patent protection for Keytruda extending into 2028. The principal composition-of-matter protection is the central barrier to direct biosimilar substitution during the first post-exclusivity period. [1]
Method-of-use patents
Method patents cover treatment of specific cancers, biomarker-defined populations, dosing schedules, combination therapies, and perioperative use. These patents may extend beyond the core antibody patent and can create litigation risk for biosimilar applicants even when the applicant seeks approval for only selected indications.
Method-of-use claims are commercially important because a 351(k) applicant can pursue a so-called skinny label that omits patented indications. That approach reduces infringement exposure but does not eliminate risk where physicians use the product for patented treatments or where product labeling and market conduct support an induced-infringement theory.
Formulation and delivery patents
Formulation patents can cover:
- Concentrated pembrolizumab solutions.
- Stabilizers and excipients.
- Ready-to-use intravenous presentations.
- Subcutaneous delivery systems.
- Co-formulations with enzymes or other delivery technologies.
- Manufacturing and fill-finish processes.
These patents are relevant to biosimilar manufacturers seeking lower-cost production or differentiated administration. They may not block every biosimilar version, but they can delay or narrow competitive entry.
Is Keytruda listed in the Orange Book?
Keytruda is not listed in the FDA Orange Book because pembrolizumab is a biologic licensed under a BLA rather than a small-molecule drug approved under an NDA. Biologic patent information is handled through the FDA's Purple Book framework and the BPCIA patent-exchange process. [3, 4]
This distinction affects litigation mechanics:
- Small-molecule generics typically rely on Orange Book patent certifications, including Paragraph IV certifications.
- Biosimilar applicants do not file Paragraph IV certifications for Keytruda.
- Biosimilar disputes proceed through the BPCIA's patent-information exchange and related federal litigation.
- The reference-product sponsor may sue before or after FDA approval, depending on the exchange process and asserted patents.
Are there Paragraph IV challenges to pembrolizumab?
There is no conventional Paragraph IV pathway for pembrolizumab because Keytruda is a biologic. The relevant challenge is a 351(k) biosimilar application, not an abbreviated new drug application with a Paragraph IV certification.
The commercial equivalent of a Paragraph IV challenge is a biosimilar applicant's effort to establish that:
- The reference product's patents are invalid.
- The patents are not infringed.
- The patents are unenforceable.
- The applicant can omit patented indications.
- The applicant can launch after a negotiated settlement date.
The timing of biosimilar litigation will depend on the filing dates and patent disclosures of individual applicants. A public statement that a company is developing pembrolizumab does not establish a launch right.
Which companies compete with pembrolizumab?
Pembrolizumab competes mainly with other PD-1 or PD-L1 checkpoint inhibitors. The relevant products include Bristol Myers Squibb's Opdivo and Opdualag, Roche's Tecentriq, AstraZeneca's Imfinzi, Regeneron's Libtayo, GlaxoSmithKline's Jemperli, and Pfizer's Bavencio.
| Product |
Active agent |
Company |
Main competitive position |
| Keytruda |
Pembrolizumab |
Merck |
Broadest indication base and largest commercial scale |
| Opdivo |
Nivolumab |
Bristol Myers Squibb |
Major PD-1 competitor with broad oncology use |
| Tecentriq |
Atezolizumab |
Roche |
PD-L1 product with established lung and urothelial uses |
| Imfinzi |
Durvalumab |
AstraZeneca |
Strong lung cancer and biliary tract positioning |
| Libtayo |
Cemiplimab |
Regeneron and Sanofi |
Focused use in selected solid tumors |
| Jemperli |
Dostarlimab |
GSK |
Stronger position in mismatch-repair-deficient endometrial cancer |
| Bavencio |
Avelumab |
Pfizer |
Narrower commercial footprint |
Keytruda's primary competitive advantage is not only the PD-1 mechanism. It is the accumulated clinical evidence, physician familiarity, companion-diagnostic infrastructure, payer coverage, and breadth of combination data.
What licensing deals affect pembrolizumab's future value?
Merck's most important external immuno-oncology transaction is its collaboration with Moderna on V940, also known as mRNA-4157, an individualized neoantigen therapy combined with pembrolizumab. The companies entered a strategic agreement in 2022 after reporting positive early-stage data in melanoma. The agreement gave Merck worldwide commercial rights outside certain retained economics and included an upfront payment and potential milestone payments. [5]
The commercial rationale is defensive and expansionary. A personalized cancer vaccine used with pembrolizumab can increase the value of the existing checkpoint inhibitor while creating a new treatment platform. The risk is that the combination may improve outcomes without preserving the full price of Keytruda after biosimilar competition arrives.
Merck also uses internal and external combination development to expand Keytruda into earlier settings. These programs increase the number of treatment episodes but can expose the franchise to clinical trial failure, reimbursement restrictions, and combination-product competition.
What biosimilar entry risks exist for pembrolizumab?
The first competitive wave is likely to target intravenous pembrolizumab. The key risks are:
Price erosion
Biosimilar competition could reduce net prices through hospital contracting, group purchasing, payer formularies, and government tenders. The degree of erosion will depend on the number of approved products and whether interchangeability is established.
Switching and substitution
Unlike small-molecule generics, biosimilar substitution is governed by state pharmacy laws and FDA interchangeability determinations. Oncology administration is usually controlled by oncologists and infusion centers, which may slow automatic substitution but strengthen institutional purchasing leverage.
Indication carve-outs
Biosimilar applicants can omit patented indications from their labels. This may permit entry into older or less protected indications while leaving newer perioperative or combination indications with continued patent protection.
Manufacturing barriers
Pembrolizumab is a complex monoclonal antibody. Biosimilar developers must demonstrate analytical similarity, control glycosylation and aggregation, establish reliable cell culture and purification processes, and secure global manufacturing capacity. These barriers support a smaller competitor set than in conventional generic markets.
How strong is the pembrolizumab patent estate?
The estate is commercially strong through the late 2020s because it combines a high-value composition patent, extensive method-of-use coverage, regulatory exclusivity, and a large clinical label. Its strength is weaker against targeted carve-out strategies after the core patent expires.
| Estate component |
Commercial strength |
Main limitation |
| Antibody composition |
High through core expiry |
Central patent expires before some later-use patents |
| FDA biologic exclusivity |
High through 2026 |
Does not prevent later biosimilar filing indefinitely |
| Method-of-use claims |
Moderate to high |
Vulnerable to skinny-label strategies |
| Formulation claims |
Moderate |
May not block materially different formulations |
| Manufacturing claims |
Moderate |
Competitors can design around process claims |
| Combination patents |
Variable |
Dependent on claim scope and clinical indication |
The most important question is not whether Keytruda has patents after 2028. It is whether those patents cover the commercial indications that account for the largest share of prescriptions.
What generic or biosimilar launch scenarios exist?
A practical launch framework has three scenarios:
| Scenario |
Timing |
Commercial effect |
| Early negotiated entry |
Around core patent expiry |
Moderate initial discounts and gradual share loss |
| Limited indication entry |
Before full estate expiry |
Selective hospital and payer competition |
| Broad post-litigation entry |
After patent disputes conclude |
Faster price erosion and multi-product tender competition |
A single biosimilar launch would not necessarily replicate the erosion pattern of a small-molecule generic. The product is administered in oncology settings, has multiple dosing schedules, and is embedded in combination protocols. However, Keytruda's size makes it an attractive target for multiple developers, increasing the probability of competitive contracting once legal barriers fall.
What is the geographic patent and market outlook?
The United States is the largest value pool and the main source of loss-of-exclusivity risk. Europe is expected to retain protection later than the U.S. under Merck's reported patent timetable, but European revenue is more exposed to centralized procurement and price negotiations. Japan and other Asian markets have separate patent, regulatory, and reimbursement timelines.
Global erosion will not occur on one date. It will vary by:
- Local patent term.
- Supplementary protection certificates.
- Biosimilar approval timing.
- Hospital tender structure.
- Interchangeability rules.
- National reimbursement policy.
- Local manufacturing requirements.
What is the revenue exposure if Keytruda loses exclusivity?
Keytruda's $29.5 billion 2024 revenue creates a major concentration risk for Merck. The franchise represented roughly $1 of every $2 of pharmaceutical revenue. A 10% decline in Keytruda sales would represent approximately $3 billion in annual revenue loss before offsetting growth from other products. A 30% decline would represent approximately $8.9 billion.
Merck's response is centered on pipeline replacement, especially Winrevair, Gardasil, animal-health assets, and new oncology products. The company also seeks to extend pembrolizumab's economic life through combinations, new delivery methods, and expanded perioperative use. [1]
Key Takeaways
- Keytruda generated approximately $29.5 billion in 2024 sales.
- Revenue increased at an approximately 19% compound annual rate from 2020 through 2024.
- FDA biologic exclusivity runs to approximately September 2026.
- Merck reports core U.S. patent protection through 2028 and protection in major European markets through approximately 2030.
- Keytruda is governed by the Purple Book and BPCIA, not the Orange Book and Paragraph IV process.
- Biosimilar risk will depend on patent litigation, indication carve-outs, interchangeability, and hospital contracting.
- The patent estate is strongest for the antibody and older uses, while later method-of-use and formulation patents may support partial protection.
- Merck's principal lifecycle strategy is to preserve volume through earlier-line treatment, combinations, and next-generation delivery.
- The financial exposure is material: a 10% Keytruda sales decline would equal roughly $3 billion based on 2024 revenue.
FAQs About Pembrolizumab Market and Patent Risk
What is the expected peak sales level for Keytruda?
Keytruda was still growing at 18% in 2024, but peak sales will depend on the pace of label expansion, international growth, and the timing of biosimilar entry. Merck has not established a single definitive public peak-sales figure that determines the franchise's terminal value.
Can a pembrolizumab biosimilar launch before 2028?
FDA approval could occur before 2028 if statutory exclusivity has expired and patent barriers are resolved. Commercial launch could still be delayed by litigation, settlement agreements, injunctions, or product-specific patents.
Does Keytruda have interchangeable biosimilars?
No interchangeable pembrolizumab biosimilar had established U.S. market status in the cited reporting period. Interchangeability requires a separate FDA determination and can affect automatic substitution at the state level.
Which cancer indication is most important to Keytruda revenue?
Non-small cell lung cancer is among the most commercially important indications because of its large patient population, extensive combination use, and adoption across multiple treatment lines. Merck does not publicly allocate total Keytruda revenue by indication.
Could subcutaneous pembrolizumab reduce biosimilar erosion?
A differentiated delivery system could preserve part of the franchise by improving convenience and creating new patent claims. It would not eliminate biosimilar pressure on the existing intravenous product and may face separate reimbursement and patent challenges.
References
-
Merck & Co., Inc. (2025). 2024 annual report. https://www.merck.com/annual-reports/
-
U.S. Food and Drug Administration. (2024). Keytruda (pembrolizumab) prescribing information and approvals. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
Merck & Co., Inc., & Moderna, Inc. (2022). Merck and Moderna announce strategic collaboration to develop personalized cancer vaccine. https://www.merck.com/news/
